Non-Hodgkin Lymphoma
News
Combo prolongs survival in lymphoma models
Combination treatment with 2 monoclonal antibodies (mAbs) has demonstrated preclinical efficacy against B-cell lymphomas, according to researchers...
News
Inhibitor exhibits activity against range of lymphomas
Preclinical research suggests the dual PI3K/mTOR inhibitor PQR309 has activity against several types of lymphoma and works well in combination...
News
Mogamulizumab BLA receives priority review
The US Food and Drug Administration (FDA) has accepted for priority review the biologics license application (BLA) for mogamulizumab....
News
How CLL patients weigh treatment efficacy, safety, and cost
New research suggests patients with chronic lymphocytic leukemia (CLL) are willing to trade treatment efficacy for a reduced risk of side effects...
News
Review suggests low incidence of BIA-ALCL in Canada
Results of a safety review suggest there is a low incidence of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) in Canada....
News
CCSs have increased risk of hypertension
A study of childhood cancer survivors (CCSs) suggests these individuals have an increased risk of developing hypertension as adults. The CCSs...
News
Method identifies effective treatments for leukemias, lymphomas
An ex vivo drug screening method can reveal optimal therapies for patients with hematologic malignancies, according to research published in The...
News
FDA expands approval of obinutuzumab
The US Food and Drug Administration (FDA) has expanded the approved use of obinutuzumab (Gazyva®). The drug is now approved for use in...
News
CHMP wants to expand use of BV to include CTCL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approved indication for...
News
FDA approves brentuximab vedotin for pcALCL, MF
The US Food and Drug Administration (FDA) has expanded the approved use of brentuximab vedotin (BV, ADCETRIS). BV is now approved for adults with...
Conference Coverage
Ibrutinib sustains efficacy in CLL at 4-year follow-up
NEW YORK, NY—The 4-year follow-up of the RESONATE trial suggests ibrutinib may provide long-term efficacy in previously treated patients with...